硝酸舍他康唑乳膏治疗婴幼儿念珠菌性皮炎的疗效观察

目的观察硝酸舍他康唑乳膏治疗婴幼儿念珠菌性皮炎的临床疗效和安全性。方法入选26例0~3岁念珠菌性皮炎的患儿,均经临床表现及真菌学检查确诊,外用硝酸舍他康唑乳膏2次/d,连续7~14 d,观察其临床疗效及治疗前后真菌学变化。结果 26例患儿治疗7 d临床评分均值由6分下降至1.35分,下降幅度超过75%。治疗7 d临床痊愈率为57.69%,有效率为92.3%,真菌学阴转率为88.46%;14 d临床痊愈率为92.3%,真菌学阴转率为92.3%。停药后第14天随访痊愈患儿91.67%未见复发。仅1例患儿出现不良反应。结论硝酸舍他康唑乳膏治疗婴幼儿皮肤念珠菌病安全、有效,不良反应少,值得临床推广。     

硝酸舍他康唑乳膏联合中药外洗方治疗手足癣及体股癣疗效观察

目的 观察硝酸舍他康唑乳膏联合中药外洗方治疗手足癣及体股癣的疗效.方法 采用随机、单盲、平行对照法,分别将111例手足癣及112例体股癣患者分为3组,硝酸舍他康唑乳膏联合自拟中药洗方组(联合组)、硝酸舍他康唑乳膏组(对照1组)及自拟中药洗方组(对照2组),均2次/d,疗程2周.在停药时和停药1周后根据临床症状、体征及真菌清除率判定疗效.结果 停药时和停药1周后联合组中手足癣患者的总有效率分别为92.50％、95.00％,体股癣患者分别为92.86％、97.62％;对照1组中手足癣患者的总有效率分别为86.11％、91.67％,体股癣患者分别为89.47％、92.11％;对照2组中手足癣患者的总有效率分别为68.57％、71.43％,体股癣患者分别为68.75％、71.86％.联合组、对照1组临床疗效均明显优于对照2组,差异有显著性(P＜0.05);联合组临床疗效略高于对照1组,差异无显著性(P＞0.05).结论 硝酸舍他康唑乳膏联合中药外洗方治疗手足癣及体股癣临床效果好,但与单用硝酸舍他康唑乳膏无显著差异性.提示硝酸舍他康唑乳膏联合中药外洗方治疗手足癣及体股癣的疗效主要源于硝酸舍他康唑乳膏.     

硝酸舍他康唑乳膏治疗婴幼儿花斑糠疹临床疗效观察

目的观察硝酸舍他康唑乳膏治疗婴幼儿花斑糠疹的疗效及安全性。方法入选的50例0~3岁花斑糠疹的患儿,均经真菌学检查及临床表现确诊,外用硝酸舍他康唑乳膏,2次/d,连用1~2周,观察其治疗后的真菌学变化及临床疗效。结果 50例完成治疗观察的患儿,一周真菌清除率为40%,临床有效率为48%;2周真菌清除率96%,临床有效率92%。停药后2周随访有效患儿无复发。仅2例出现轻微不良反应。结论硝酸舍他康唑乳膏治疗婴幼儿花斑糠疹疗效肯定,安全性高,值得临床推广。     

硝酸舍他康唑的临床应用研究进展

硝酸舍他康唑(sertaconazole)是一种新型、广谱、高效的外用唑类抗真菌药。本文就其药理作用、抗炎、止痒、抗真菌临床疗效及安全性评价等方面加以综述。新的剂型-微乳凝胶,增强皮肤渗透性和存留时间,而且能减少对皮肤的刺激。外用硝酸舍他康唑治疗皮肤癣菌病和浅表念珠菌感染见效快,治愈率高,疗程短。根据药代动力学,舍他康唑只需每日用药一次,加之其止痒活性,增加了患者依从性,从而提高了临床治愈率。最新临床研究发现外用硝酸舍他康唑乳膏对脂溢性皮炎、特应性皮炎有良好的疗效。     

硝酸舍他康唑乳膏每日1次疗法治疗股癣疗效观察

目的 观察舍他康唑乳膏1次/d疗法治疗股癣的效果与安全性.方法 将参与试验的股癣患者随机分组,试验组每晚1次外用舍他康唑乳膏,对照组早晚各1次外用舍他康唑乳膏,连续用药4周,于治疗前、用药2周、4周及停药后2周分别进行症状和体征评分.结果 治疗结束和停药2周时,两组的临床疗效无显著差异(P＞0.05).治疗2周时试验组和对照组的真菌清除率分别为82.6％和92.5％,有显著差异(P＜0.05);治疗结束和停药2周时试验组的真菌清除率分别为95.9％和97.3％,对照组分别为96.4％和98.6％,均无显著差异(P＞0.05).结论 舍他康唑乳膏1次/d疗法治疗股癣疗效好,简便易行,安全性高.     

溻洗散治疗足癣的临床疗效观察及体外抑菌实验研究

目的探讨中药溻洗散治疗足癣的临床疗效及其对常见浅部真菌的抑制作用。方法入组167例足癣患者,随机分为试验组83例,对照组84例。试验组外用溻洗散联合硝酸舍他康唑乳膏,对照组外用硝酸舍他康唑乳膏,2次/d,疗程4周,于治疗前、治疗4周、停药2周时评价两组临床症状和体征评分、起效时间、总有效率、真菌清除率等。采用微量稀释法测定溻洗散对红色毛癣菌、须癣毛癣菌和白念珠菌的最低抑菌浓度。结果试验组与对照组总有效率分别为92.8%、82.1%,两组比较差异有统计学意义(P0.05),试验组起效时间短于对照组(P0.01)、真菌清除率高于对照组(P0.05)。溻洗散对体外培养白念珠菌、红色毛癣菌和须癣毛癣菌均有抑制作用,MIC分别为0.125 g/mL、0.5 g/mL和0.25 g/mL。结论溻洗散治疗足癣临床疗效确切,对常见皮肤浅部真菌具有抑制作用,可在临床推广和应用。     

2%硝酸舍他康唑乳膏治疗体股癣和足癣疗效和安全性评价

目的 评价2％硝酸舍他康唑乳膏治疗足癣和体、股癣的疗效及安全性,并与2％硝酸咪康唑乳膏对照。方法 采用多中心随机双盲对照试验。试验组及对照组分别外用2％硝酸舍他康唑乳膏和2％硝酸咪康唑乳膏,每天2次,疗程4周。在治疗开始及治疗2周、4周、6周时进行观察。结果 足癣试验组61例,对照组58例;体、股癣试验组56例,对照组55例完成了观察。足癣在4周时,临床有效率试验组98．36％,对照组93．10％,在6周时分别为100％和98．28％;在4周和6周时真菌学清除率试验组均为95．1％,对照组均为100％;在4周时总有效率试验组98．36％,对照组93．10％,在6周时分别为100％和98．28％。体、股癣在4周时,临床有效率试验组98．21％,对照组92．73％,在6周时分别为100％和98．18％;在4周和6周时真菌学清除率试验组和对照组均为100％;在4周时总有效率试验组98．21％,对照组92．73％,在6周时分别为100％和98．18％。药物不良反应发生率试验组1．7％,对照组0．9％,表现为局部刺激。结果 显示2％硝酸舍他康唑乳膏治疗足癣和体、股癣的疗效及安全性与2％硝酸咪康唑乳膏相似（P〉0．05）。结论 2％硝酸舍他康唑乳膏治疗足癣和体、股癣有效、安全。     

系统性红斑狼疮继发泛发性浅部真菌病1例

患者,女,57岁。既往系统性红斑狼疮病史18a。躯干出现片状红斑、鳞屑瘙痒3a。经口服伊曲康唑,硝酸舍他康唑乳膏外用治疗体癣,以及点阵激光联合硝酸舍他康唑乳膏封包治疗甲癣9周后痊愈,复查真菌阴性。     

念珠菌性包皮龟头炎56例临床分析

目的 了解念珠菌性包皮龟头炎的临床特点、诱发因素、菌种分布及治疗.方法 对本院性病门诊中确诊的56例念珠菌性包皮龟头炎患者的临床和实验室资料进行回顾性分析,总结临床特征、诱发因素、菌种分布及治疗经验.结果 56例念珠菌性包皮龟头炎发病平均年龄(34.11±9.92)岁,25～ 40岁青年人占67.9％ (38/56);包皮过长者87.5％ (49/56),有糖尿病史14.29％ (8/56).56例患者念珠菌培养阳性48人(85.71％),共分离到49株念珠菌,其中白念珠菌44株(91.84％),近平滑念珠菌4例(8.16％).所有患者予舍他康唑乳膏外用,5例症状严重患者联合伊曲康唑口服,76.79％(43/56)的患者获得临床和真菌学治愈,1个月后随访无复发.结论 念珠菌性包皮龟头炎好发于青年人,白念珠菌仍是其最常见的病原菌,外用舍他康唑乳膏临床获得较好的疗效,为提高治愈率和避免再感染,治疗期间应避免性行为.     

2％硝酸舍他康唑乳膏联合复方酮康唑乳膏治疗手足癣的疗效观察

手、足癣是皮肤癣菌在手足部位引起的皮肤病,在全世界广泛流行,发病率高、局部传染性强.外用抗真菌药物是目前临床采用的主要的治疗方法.笔者利用硝酸舍他康唑乳膏联合复方酮康唑乳膏治疗手、足癣82例,现对其疗效和安全性报告如下.     

The Efficacy and Safety of Sertaconazole Cream (2 %) in Diaper Dermatitis Candidiasis

Aim

Diaper dermatitis (DD) is an inflammatory irritating condition that is common in infants. Most cases are associated with the yeast colonization of Candida or diaper dermatitis candidiasis (DDC), and therefore, the signs and symptoms improve with antimycotic treatment. Sertaconazole is a broad-spectrum third-generation imidazole derivative that is effective and safe for the treatment for superficial mycoses, such as tineas, candidiasis, and pityriasis versicolor. Our goal was to assess the efficacy and safety of sertaconazole cream (2 %) in DDC.

Materials and methods

Twenty-seven patients with clinical and mycological diagnosis of DDC were enrolled and treated with 2 daily applications for 14 days and were followed-up for 2 further weeks.

Results

Three etiologic agents were isolated: Candida albicans in 88.8 %, Candida parapsilosis in 7.3 %, and Candida glabrata in 3.2 %. There was an average symptom reduction from 7.1 to 3.2 in the middle of treatment and to 1.2 and 0.4 units at the end of treatment and follow-up, respectively. The treatment evaluation at the end of the follow-up period showed a total clinical and mycological cure in 88.8 %, improvement in 3.7 %, and failure in 7.4 %. There was side effect (3.7 %) of skin irritation, but the drug was not discontinued.

Conclusions

Based on its safety and effectiveness, sertaconazole cream may be considered a new alternative for DDC treatment.     

伊曲康唑联合外用药物治疗花斑糠疹临床研究

目的探讨伊曲康唑胶囊联合1%盐酸布替萘芬乳膏和2%酮康唑洗剂治疗花斑糠疹的疗效及不良反应。方法入选患者按单双日分为两组,两组均口服伊曲康唑0.2g,1次/d,连续7d,同时外用1%盐酸布替萘芬乳膏,1次/d,连续14d,对照组停药观察,试验组同时使用2%酮康唑洗剂洗浴,每周2次,连用3个月。分别于治疗前、治疗后1、3、6、12个月评价疗效。结果试验组114例患者3个月时痊愈率78.1%,6个月时痊愈率90.4%,对照组125例患者3个月时痊愈率72.8%,6个月时痊愈率75.2%,12个月后试验组复发率1.8%,对照组为18.4%。结论伊曲康唑胶囊短时口服联合外用布替萘芬和酮康唑洗剂洗浴疗效较好,安全性高,使用方便,可大大降低花斑糠疹的复发率。     

Efficacy and safety of Indigo naturalis extract in oil (Lindioil) in treating nail psoriasis: A randomized,observer-blind,vehicle-controlled trial

Treating nail psoriasis is notoriously difficult and lacks standardized therapeutic regimens. Indigo naturalis has been demonstrated to be safe and effective in treating skin psoriasis. This trial was conducted to evaluate the efficacy and safety of refined indigo naturalis extract in oil (Lindioil) in treating nail psoriasis. Thirty-one outpatients with symmetrically comparable psoriatic nails were enrolled. Lindioil (experimental group) or olive oil (control group) was applied topically to the same subjects’ two bilaterally symmetrical psoriatic nails twice daily for the first 12 weeks and then subjects applied Lindioil to both hands for 12 additional weeks. Outcomes were measured using Nail Psoriasis Severity Index (NAPSI) for five nails on one hand and for the single most severely affected nail from either hand. The results show a reduction of NAPSI scores for the 12-week treatment for the Lindioil group (49.8% for one hand and 59.3% for single nail) was superior to the reduction in the scores for the control group (22.9%, 16.3%, respectively). There were no adverse events during the 24 weeks of treatment. This trial demonstrates that Lindioil is a novel, safe and effective therapy for treating nail psoriasis.     

萘替芬酮康唑乳膏每日1次治疗足癣疗效观察

目的观察萘替芬酮康唑乳膏1次/d治疗足癣的效果与安全性。方法将参与试验的足癣患者随机分组,试验组每晚1次外用萘替芬酮康唑乳膏,对照组早晚各1次外用萘替芬酮康唑乳膏。连续用药4周,于治疗前,用药2周、4周及停药2周后分别进行症状和体征评分。结果治疗结束和停药2周时,两组的临床疗效无显著差异(P>0.05)。治疗2周时试验组和对照组的真菌清除率分别为78.6%和90.3%,有显著差异(P<0.05);治疗结束和停药2周时试验组的真菌清除率分别为92.9%和97.6%,对照组分别为94.4%和98.6%,均无显著差异(P>0.05)。结论萘替芬酮康唑乳膏1次/d治疗足癣疗效好,简便易行,安全性高。     

Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised,double blind,parallel group study

Objective To explore the efficacy and safety of fluticasone propionate, cream and ointment, applied twice weekly in addition to maintenance treatment with emollients, in reducing the risk of relapse of chronic recurrent atopic dermatitis.Design Randomised, double blind, parallel group study of 20 weeks'' duration.Setting Dermatology outpatient clinics (6 countries, 39 centres).Participants Adult (aged 12-65) patients with moderate to severe atopic dermatitis who were experiencing a flare.Methods Participants applied fluticasone propionate (0.05% cream or 0.005% ointment; once or twice daily) regularly for four weeks to stabilise their condition. The patients whose disease was brought under control then continued into a 16 week maintenance phase, applying emollient on a daily basis with a bath oil as needed and either the same formulation of fluticasone propionate or its placebo base (emollient alone) twice weekly to the areas that were usually affected.Main outcome measure Time to relapse of atopic dermatitis during maintenance phase.Results 376 patients entered the stabilisation phase, and 295 continued into the maintenance phase. After 16 weeks in the maintenance phase, the disease remained under control in 133 patients (87 using fluticasone propionate twice weekly, 46 using emollient alone), 135 (40 fluticasone propionate, 95 emollient) had experienced a relapse, and 27 had discontinued. Median time to relapse was six weeks for emollient alone compared with more than 16 weeks for additional fluticasone propionate. Patients who applied fluticasone propionate cream twice weekly were 5.8 times less likely (95% confidence interval 3.1 to 10.8, P < 0.001) and patients using fluticasone propionate ointment 1.9 times less likely (1.2 to 3.2, P=0.010) to have a relapse than patients applying emollient alone. The groups showed no differences in adverse events.Conclusion After atopic dermatitis had been stabilised the addition of fluticasone propionate twice weekly to maintenance treatment with emollients significantly reduced the risk of relapse.     

Achievement of complete mycological cure by topical antifungal agent NND-502 in guinea pig model of tinea pedis

We examined the therapeutic effect of a 1% cream preparation of NND-502, a novel topical antifungal agent, in a guinea pig tinea pedis model produced by infecting the plantar skin of guinea pigs with Trichophyton mentagrophytes. Animals developing tinea pedis were divided into two groups: an untreated control group and a treated group. In the latter group, after confirming infection had been established, the infected animals were topically treated with the NND-502 cream once daily for one week. The animals were reared in a clean environment free from exposure to exogenous dermatophytes. At one week (5 weeks post-infection), 6 weeks (10 weeks post-infection) and 16 weeks (20 weeks post-infection) after completion of the treatment, plantar skin samples were taken from a certain number of both groups of animals. The results demonstrated that all of the animals in the untreated control group and none of those in the treated group were culture-positive in this animal model of tinea pedis. The topical treatment with NND-502 achieved a mycological cure. Thus NND-502 can be considered a promising candidate as a new anti-dermatophytic agent for topical use.     

依达拉奉联合疏血通对急性脑梗死患者的临床疗效及机制研究

目的:探讨依达拉奉联合疏血通对急性脑梗死患者的临床疗效及其可能作用机制。方法:收集我院治疗的80例急性脑梗死患者,随机分为实验组和对照组,每组40例。对照组患者给予依达拉奉注射液30 mg+生理盐水100 mg静脉滴注,2次/d;实验组患者在对照组基础上给予疏血通注射液6 g+生理盐水250 m L静脉滴注,2次/d,14 d为1个疗程。治疗后,对两组患者的血清血清基质金属蛋白酶-9(MMP-9),血管内皮生长因子(VEGF)、NIHSS以及临床疗效进行检测并比较。结果:与治疗前相比,两组患者治疗后血清MMP-9、VEGF水平以及NIHSS评分均显著下降(P0.05);与对照组相比,实验组患者治疗后血清MMP-9、VEGF水平以及NIHSS评分均较低(P0.05),且治疗总有效率较高(P0.05)。结论:依达拉奉联合疏血通能够有效提高急性脑梗死患者的临床疗效,改善神经功能缺损,这可能与其降低患者血清基质金属蛋白酶-9(MMP-9)及血管内皮生长因子(VEGF)水平有关。     

Anti-photoaging effect of skin cream manufactured with ziyuglycoside I isolated from Sanguisorba officinalis on ultraviolet B-induced hairless mice

In this study, skin cream containing ziyuglycoside I isolated from Sanguisorba officinalis was manufactured and examined the protective effects of the skin cream against UVB-induced hairless mice. UVB-induced hairless mice were topically treated with the skin cream once a day for 5 weeks. Application of the skin cream did not exhibit side effect on body growth showing normal body weight and food efficiency in the mice. The skin cream treatment also was inhibited mRNA expression of interleukin (IL)-1β, matrix metalloproteinase (MMP)-2, MMP-9, and MMP-2 protein expression in the mice. Furthermore, the skin cream treatment inhibits epidermal wrinkle formation, wrinkle depth, wrinkle thickness, and collagen degradation in UVB-induced hairless mice. Therefore, the skin cream was able to play a role in the attenuation of photoaging caused by UVB irradiation via downregulation of mRNA expression of inflammatory cytokine IL-1β, MMP-2, MMP-9, and suppression of MMP-2 proteins expression.